CLINICAL RESEARCH IN CARDIOLOGY, cilt.100, ss.571-577, 2011 (SCI İndekslerine Giren Dergi)
Levosimendan is a promising new inodilator agent but its effectiveness in peripartum cardiomyopathy (PPCM) has not been tested in a clinical trial. The authors sought to evaluate the effect of levosimendan therapy and to determine the predictors of clinical outcome in patients with PPCM.